Strategic collaboration leverages CluePoints’ Central Statistical Monitoring (CSM) technology to enhance data quality and reduce operational costs
Parexel and CluePoints have announced a strategic collaboration to improve Parexel’s offerings with enhanced statistical capabilities.
US-based Parexel provides clinical, consulting and commercial solutions for new therapies, while CluePoints delivers Risk-Based Study Execution (RBx) and data quality oversight software.
Through the collaboration, Parexel and CluePoints aim to drive the quality, accuracy, and integrity of clinical trial data both during and after study conduct as well as increase productivity, efficiency and cost-effectiveness for sponsors.
“Our vision of RBx, where independent data interrogation, comprehensive analysis, and resulting actions become reusable knowledge, is enabling the industry to progress efficiencies and further improve quality for sponsors,” said Patrick Hughes, CCO at CluePoints.
Gadi Saarony, Executive VP and Chief Clinical Research Services Officer at Parexel explained the benefits to Parexel: “A proactive risk management strategy to protect patient safety and ensure high-quality data is at the foundation of every clinical trial we conduct.”
Saaront explained that CluePoints’ CSM solution will give the company a new outlook on Risk-Based Monitoring (RBM) from a holistic point of view. The partnership is also intended to allow Parexel to focus on monitoring activities where they are needed, ultimately driving increased efficiency and productivity while identifying and addressing risks before problems arise.